Sectors

ESLA
Estrella Immunopharma, Inc.
0.72
1 x 1.14
2 x 0.75
bid
ask
+
0.01
2.11%
09:37 AM
timesize
Ytd-53.85%
1y-31.43%
0.66
day range
0.73
0.63
52 week range
3.15
Open0.68Prev Close0.71Low0.66High0.73Mkt Cap31.32M
Vol6.42KAvg Vol40.18KEPS-0.25P/EN/AForward P/EN/A
Beta0.88Short Ratio0.07Inst. Own0.55%DividendN/ADiv YieldN/A
Ex Div DateN/AEarningN/A50-d Avg0.82200-d Avg1.241yr Est0.00

ESLA News

Estrella Immunopharma (NASDAQ:ESLA) Trading Up 1.1%  – Should You Buy?
defenseworld.net
Estrella Immunopharma (NASDAQ:ESLA) Trading Up 1.1% – Should You Buy?

Shares of Estrella Immunopharma, Inc. (NASDAQ: ESLA - Get Free Report) shot up 1.1% during trading o

Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
businesswire.com
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Sit

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday&#

benzinga.com
Estrella Immunopharma Activates Third Clinical Site For Ongoing STARLIGHT-1 Phase I/II Clinical Tria

Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical-

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
businesswire.com
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

benzinga.com
Estrella Immunopharma Activates Second Clinical Facility For Its Current STARLIGHT-1 Phase I/II Clin

Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical

Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
businesswire.com
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

benzinga.com
Estrella Immunopharma Doses First Participant In Its Current STARLIGHT-1 Phase I/II Clinical Study O

Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical

Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin's Lymphoma
businesswire.com
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers Crinetics Pharmaceuticals (NASDAQ:CRNX) stock increased by 98.9% to $83.59 during Tuesday&#

benzinga.com
Estrella Immunopharma Q1 EPS $(0.05) Beats $(0.18) Estimate

Estrella Immunopharma (NASDAQ:ESLA) reported quarterly losses of $(0.05) per share which beat the an

Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
businesswire.com
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” o

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
businesswire.com
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/S

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” o

12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session

benzinga.com
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $8 Price Target

D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy a

12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
businesswire.com
Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tand

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #2026TandemMeetings--Estrella Immunopharma, Inc. (Nasdaq: ESLA

Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
benzinga.com
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®
businesswire.com
Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB10

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (Nasdaq: ESLA) (“Estrella” or the “

benzinga.com
D. Boral Capital Maintains Buy on Estrella Immunopharma, Lowers Price Target to $8

D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy a

Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
businesswire.com
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Pr

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (the “Company

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
businesswire.com
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (the “Company”), a c

benzinga.com
Estrella Immunopharma Offers Up To 2,541,206 Shares For Resale By The Selling Stockholders

ESTRELLA IMMUNOPHARMA, INC.Up to 2,541,206 Shares of Common StockThis prospectus relates to the offe

Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast
defenseworld.net
Estrella Immunopharma (NASDAQ:ESLA) & Foghorn Therapeutics (NASDAQ:FHTX) Head-To-Head Contrast

Foghorn Therapeutics (NASDAQ: FHTX - Get Free Report) and Estrella Immunopharma (NASDAQ: ESLA - Get

benzinga.com
Estrella Immunopharma Recommended By Independent Data Safety Monitoring Board To Advance STARLIGHT-1

Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
businesswire.com
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

benzinga.com
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target

D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy a

benzinga.com
Estrella Immunopharma Completes Second Dose Cohort In STARLIGHT-1 Phase I/II Clinical Trial Of EB10

Key Findings:The study has achieved a 100% complete response (CR) rate at Month 1 in all evaluable p

Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
businesswire.com
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Respo

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session

benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
businesswire.com
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

benzinga.com
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target

D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy a

benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin's Lymphomas
businesswire.com
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
businesswire.com
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “

Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort
businesswire.com
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Init

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” o

Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital
businesswire.com
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target o

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” o

benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session

Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS® T-cells
businesswire.com
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTE

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” o

benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session